Skip to main content
Top
Published in: Diabetologia 10/2011

01-10-2011 | Commentary

Type 2 diabetes: remission in just a week

Author: H. Yki-Järvinen

Published in: Diabetologia | Issue 10/2011

Login to get access

Excerpt

We have learnt that type 2 diabetes can be prevented by maintaining a healthy lifestyle [1, 2]. Such therapy is inexpensive and without side effects. Regarding patients with established type 2 diabetes, we often dream of a magic pill that would permanently solve the problem. We might perhaps view type 2 diabetes as a point of no return when we look at long-term data such as those provided by the UK Prospective Diabetes Study: progressive deterioration of glycaemic control and beta cell function irrespective of therapy, be it pharmacological or non-pharmacological [3]. Even the most exciting new drugs, such as dipeptidyl-peptidase IV inhibitors or glucagon-like peptide 1 agonists, seem to fail to produce persistent improvements in beta cell function [4, 5]. On a positive note, the study of Lim et al. in this issue of Diabetologia reminds us that type 2 diabetes and its pathophysiological defects are indeed entirely reversible, at least in the short-term [6]. …
Literature
1.
go back to reference Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef
2.
go back to reference Knowler WC, Fowler SE, Hamman RF et al (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1677–1686PubMedCrossRef Knowler WC, Fowler SE, Hamman RF et al (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1677–1686PubMedCrossRef
3.
go back to reference U.K. Prospective Diabetes Study Group (1995) UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258CrossRef U.K. Prospective Diabetes Study Group (1995) UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249–1258CrossRef
4.
go back to reference Bunck M, Cornér A, Eliasson B et al (2011) Effects of exenatide on measures of β-cell function after 3 years in metformin treated patients with type 2 diabetes. Diabetes Care. doi:10.2337/dc11-0291 Bunck M, Cornér A, Eliasson B et al (2011) Effects of exenatide on measures of β-cell function after 3 years in metformin treated patients with type 2 diabetes. Diabetes Care. doi:10.​2337/​dc11-0291
5.
go back to reference Foley JE, Bunck MC, Moller-Goede DL et al (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. doi:10.1007/s00125-011-2167-8 Foley JE, Bunck MC, Moller-Goede DL et al (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. doi:10.​1007/​s00125-011-2167-8
6.
go back to reference Lim EL, Hollingswirth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. doi:10.1007/s00125-011-2204-7 Lim EL, Hollingswirth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. doi:10.​1007/​s00125-011-2204-7
7.
go back to reference Hernandez TL, Sutherland JP, Wolfe P et al (2010) Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. Am J Clin Nutr 91:578–585PubMedCrossRef Hernandez TL, Sutherland JP, Wolfe P et al (2010) Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. Am J Clin Nutr 91:578–585PubMedCrossRef
8.
go back to reference Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Klein S (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136:1552–1560PubMedCrossRef Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Klein S (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136:1552–1560PubMedCrossRef
9.
go back to reference Sevastianova K, Kotronen A, Gastaldelli A et al (2011) Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 94:104–111PubMedCrossRef Sevastianova K, Kotronen A, Gastaldelli A et al (2011) Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 94:104–111PubMedCrossRef
10.
go back to reference Albu JB, Heilbronn LK, Kelley DE et al (2010) Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes 59:627–633PubMedCrossRef Albu JB, Heilbronn LK, Kelley DE et al (2010) Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. Diabetes 59:627–633PubMedCrossRef
11.
go back to reference Vitola BE, Deivanayagam S, Stein RI et al (2009) Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver Spring) 17:1744–1748CrossRef Vitola BE, Deivanayagam S, Stein RI et al (2009) Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver Spring) 17:1744–1748CrossRef
12.
go back to reference Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38PubMedCrossRef Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38PubMedCrossRef
13.
go back to reference Colles SL, Dixon JB, Marks P, Strauss BJ, O’Brien PE (2006) Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr 84:304–311PubMed Colles SL, Dixon JB, Marks P, Strauss BJ, O’Brien PE (2006) Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr 84:304–311PubMed
14.
go back to reference Maraki M, Sidossis LS (2010) Effects of energy balance on postprandial triacylglycerol metabolism. Curr Opin Clin Nutr Metab Care 13:608–617PubMedCrossRef Maraki M, Sidossis LS (2010) Effects of energy balance on postprandial triacylglycerol metabolism. Curr Opin Clin Nutr Metab Care 13:608–617PubMedCrossRef
15.
go back to reference Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232PubMedCrossRef Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359:2220–2232PubMedCrossRef
16.
go back to reference Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC (2006) Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717–718PubMedCrossRef Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC (2006) Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29:717–718PubMedCrossRef
17.
go back to reference Hivert MF, Jablonski KA, Perreault L et al (2011) Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes 60:1340–1348PubMedCrossRef Hivert MF, Jablonski KA, Perreault L et al (2011) Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes 60:1340–1348PubMedCrossRef
Metadata
Title
Type 2 diabetes: remission in just a week
Author
H. Yki-Järvinen
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2266-6

Other articles of this Issue 10/2011

Diabetologia 10/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.